WHO ARE WE ?

CERAVER, A PIONEER IN ORTHOPAEDICS

CERAVER, a former subsidiary of the Alcatel-Alsthom group, began its activity in orthopaedics thanks to the chance meeting of a materials engineer, Daniel BLANQUAERT, and an orthopaedic surgeon, Pierre BOUTIN. This meeting marked the start of a series of innovations that would revolutionise the world of hip replacement orthopaedics.

This is how the invention of the alumina-alumina articulation total hip prosthesis came about, along with discovering the significant potential of titanium alloy TiAl6V4.

CERAVER

From innovation to experience

X.NOV SAS, based in Héricourt in Haute-Saône, France, parent company of the X.NOV Group, has just acquired 100% of the shares in CERAVER – Les Laboratoires Osteal Medical.

CERAVER, a long-established company in the medical industry, is specialized since 1988 in the design, manufacture and sale of hip and knee prostheses and associated instruments. Its unique expertise in medical ceramics has established CERAVER, under the management of Mr Blanqueart, as a technological benchmark, with products benefiting from unrivalled clinical experience on the French market.

The X.NOV group, founded in 2003, designs, manufactures and markets solutions for orthopaedic hip and knee surgery. With 275 employees, X.NOV distributes its products in over 35 countries. Its research and development capabilities and the quality of the solutions it develops are recognised by orthopaedic surgeons. Since its creation, the X.NOV group has enjoyed uninterrupted growth.

The merger between X.NOV and CERAVER marks a new stage in consolidating the X.NOV Group’s position in the European orthopaedic market, reaffirming ‘excellence à la française’.

Your patient, our priority

Since its fundation, CERAVER is a company aiming for excellence, placing patient’s well-being at its center. Supported by renowned surgeons sharing our values, our approach is based on 5 axes which are the key words of our development strategy.

Ethics and code of conduct

Our approach is based on a strict respect about:

Obligations in terms of ANTI-GIFT LAW (Art.L4113-6 of the CSP and Order of January 19, 2017)
TRANSPARENCY (Art.L1453-1 of the CSP and Decree of December 28, 2016)
Compliance with the principle of acceptability of Benefit/Risk for the patient

A French expert in orthopaedics

Based next to Paris, CERAVER has always been concerned to maintain all of its industrial activities in France. Thanks to that, design, industrial expertise, production and accreditation are all performed in France, thus respecting the regulatory requirements applied in Europe. Two production facilities totalling over 10,000m2 where last production and control technologies are implemented, ensure pursuit of excellence.

Mastery from design to manufacturing

CERAVER is the designer and manufacturer of its prostheses and associated surgical instruments. Pioneer and initiator of the use of alumina in orthopaedics, CERAVER is one of the only actors of this market to control the finishing of alumina ceramic.

This know-how and experience allow us to control the quality of our products and processes, to benefit from an optimal response time and to be totally independent.

Strict quality control and traceability

An implantable product must be of impeccable quality. This is why CERAVER’s quality system is regularly examined and certified by an independent organization according to the ISO 13485 standard.

A traceability is ensured from the primary material to the finished product allowing to follow a product during all its lifecycle (batches of primary materials, controls, results, control machines, controller, surgeon, date and place of implantation)